GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date: Wednesday, January 13, 2016
Time: 11:30 am PT
Location: Elizabethan Room B, Westin St. Francis Hotel, San Francisco
Live webcast: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20196
The webcast and replay of the presentation will also be accessible under the “Investors/Events” section of the website at novavax.com.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
Russo Partners, LLC
Todd Davenport, Ph.D.